Retatrutide experiences: results, research and independent observations

Retatrutide experiences at a glance

These are themes from personal reports and research, not a fixed set of effects. Experiences vary; clinical trials have not measured every theme in the same way.

Less hunger and earlier fullness

Reduced appetite and feeling satisfied with less food are recurring themes in Retatrutide reports. In the observation described here, smaller portions were reportedly easier to maintain.

GLP-1 and GIP contribute to the regulation of food intake and glucose processing. GLP-1 signalling is involved in satiety. Retatrutide also targets the glucagon receptor, prompting research into energy expenditure and metabolic regulation. A reported experience alone cannot establish which mechanism caused it.

Retatrutide and food noise

Food noise describes persistent mental attention to food: thinking about snacks, planning the next meal or feeling preoccupied with eating. Some personal accounts describe fewer of these thoughts.

Food noise is not an official, consistently defined clinical measure in the weight-loss studies discussed here. A personal impression is different from a prespecified, controlled trial outcome.

What do clinical studies of Retatrutide show?

Phase 2: up to 24.2% mean weight loss

The phase-2 trial by Jastreboff and colleagues included 338 adults with obesity or overweight with a weight-related condition. At 48 weeks, mean weight loss in the highest studied group was 24.2%, compared with approximately 2.1% with placebo. Group averages do not predict individual outcomes.

Read the original NEJM publication (2023).

Phase 3: new results in 2026

Lilly reported mean weight loss in TRIUMPH-1 of 19.0% in the 4 mg group and 28.3% in the 12 mg group at 80 weeks. In a prespecified extension for participants with a baseline BMI of at least 35, the 12 mg group reached a mean of 30.3% at 104 weeks.

These figures are from Lilly’s official phase-3 results and use the analysis estimating the effect of adhering to assigned treatment. The extension involved a selected group, not all participants. Studied amounts are trial data, not instructions for use. Studies with different durations and populations cannot be compared directly.

See Lilly’s official TRIUMPH-1 results (2026).

An individual Retatrutide experience: a 30.45 kg difference

PERSONAL OBSERVATION · NOT A CLINICAL TRIAL

The following data were supplied to Peptivora as a personal observation. They are separate from the trials above and have not been independently verified. The measurement method, conditions and any other substances used are not fully documented; these data cannot establish that Retatrutide caused the changes.

Starting weight on 4 May was 126.9 kg. On 5 August it was 96.45 kg: a difference of 30.45 kg, approximately 24% of starting weight. Strongly reduced appetite, little food noise and more manageable smaller portions were also reported.

This is one individual observation, not an average or guaranteed outcome for others. The rapid change in this case is not a target.

Glucose readings in the personal observation

The supplied readings are listed below. These are isolated measurements, not continuous monitoring or a standardised glucose test.

The reported post-meal readings show no conspicuously high values. This is a favourable signal within this observation, but the limited measurements cannot demonstrate stable or excellent glucose regulation throughout the period.

65 mg/dL is a low reading, not a favourable outcome. It is below the usual 70 mg/dL alert threshold and warrants medical assessment, particularly with symptoms or recurrence. Measurement error, timing, food intake and other substances can affect interpretation. These figures do not demonstrate a cure for diabetes or insulin resistance.

NIDDK: understanding low blood glucose.

What happened after stopping Retatrutide?

Does weight come straight back after stopping? That did not happen in this particular observation. At follow-up, described as about one month after stopping, measured weight was lower than on 5 August.

There was no clear rebound visible within this individual observation. Weight, body-fat percentage, fat mass and measured visceral-fat index were lower. Measured muscle mass was broadly maintained and slightly higher.

Body-composition readings are estimates affected by hydration, equipment and timing. The change from 70.0 to 70.7 kg does not prove actual muscle growth. A follow-up of about one month cannot establish long-term weight maintenance or predict what other people experience after stopping.

The lifestyle changes were maintained

According to the supplied account, the person did not return to their previous lifestyle. Adjusted food choices, adequate protein intake, portion control, physical activity and resistance training continued.

The reported progress did not automatically disappear after Retatrutide was stopped. With the adjusted lifestyle maintained, the measurements were broadly retained and several continued to fall. The separate contributions of Retatrutide, lifestyle and other factors cannot be established. This case does not show that Retatrutide prevents weight regain.

Retatrutide before and after

Before-and-after photographs can illustrate changes, but lighting, posture, clothing, hydration and camera angle affect the impression. No before-and-after photographs or simulated images have been added to this page.

Measurements add context: weight, waist circumference, body-fat percentage, fat mass, visceral fat, muscle mass and glucose. They still require consistent methods and comparable conditions. Not all these measurements are available for this case; no waist measurement was supplied, for example.

Independent research into Retatrutide

Independent academic research published in npj Metabolic Health and Disease in 2025 explored obesity-associated cancer. In a pancreatic cancer mouse model, researchers observed later measurable tumour onset and slower progression. End-point tumour volume was approximately 14-fold lower than in controls.

This was research in mice. It does not establish that Retatrutide prevents or treats cancer in humans, or shrinks existing human tumours.

Read the original research by Marathe and colleagues.

Do Retatrutide experiences differ between people?

Yes. Starting weight, age, body composition, metabolic health, food intake, physical activity, sleep, genetic factors, other substances and observation duration can all be associated with differences in outcomes.

People looking for Retatrutide experiences in the Netherlands should distinguish local personal accounts from controlled research. A story’s location does not make it representative of people in that country.

What about Retatrutide side effects?

Clinical studies reported nausea, diarrhoea, vomiting and constipation, among other adverse events. In the phase-2 trial, gastrointestinal events were more frequent at higher studied amounts. A dose-dependent increase in heart rate was also observed. This is a brief summary, not a complete safety profile.

See the safety findings in the phase-2 publication. Retatrutide remains in clinical development; personal accounts do not demonstrate that use is safe.

Can you trust Retatrutide experiences on Reddit and forums?

Forum accounts can highlight questions and experiences. However, the actual substance used, product purity, starting weight, diet, activity and other substances are often unknown. Measurement reliability may also be unclear. Striking outcomes may be shared more readily than little change.

Online experiences can provide signals, but they cannot replace controlled research.

More about Retatrutide